The Technical Analyst
Eyenovia Inc [EYEN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Eyenovia Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
7.48% $0.571
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28.88 mill |
| EPS: | -0.660 |
| P/E: | -0.860 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 50.61 mill |
| Avg Daily Volume: | 1.180 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.860 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.860 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0310 (-105.44%) $-0.602 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.409 - 0.733 ( +/- 28.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Grant Stuart M. | Buy | 100 000 | Common stock, par value $0.0001 |
| 2024-03-19 | Grant Stuart M. | Buy | 50 000 | Common stock, par value $0.0001 |
| 2024-03-08 | Grant Stuart M. | Buy | 10 717 | Common stock, par value $0.0001 |
| 2024-02-12 | Gandolfo John P | Buy | 60 000 | Stock Option (right to buy) |
| 2024-02-12 | Rowe Michael M | Buy | 75 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 69.33 |
| Last 95 transactions |
| Buy: 2 919 948 | Sell: 334 000 |
Forecast:
16:00 - $0.568
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.568
Forecast 2: 16:00 - $0.568
Forecast 3: 16:00 - $0.568
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.571 (7.48% ) |
| Volume | 1.359 mill |
| Avg. Vol. | 1.180 mill |
| % of Avg. Vol | 115.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EYEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EYEN
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Latest Press Releases
2024-04-08 07:00:00 - Press Release
Eyenovia Announces Updated Strategy And Corporate Priorities To Focus On Shareholder Value Generation And Immediate Commercial Opportunities
New york, april 08, 2024 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (micropine) and initiated a process to explore strategic alternatives to maximize shareholder value. as part of this process, the company plans to consider a wide range of options, including potential sale of assets of the company, a sale of the company, a merger, or other strategic action. in conjunction with the strategic process and focus on its late stage micropine asset, eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two fda-approved products.
2024-04-03 07:00:00 - Press Release
Eyenovia To Feature Its Suite Of Commercial Products And The Optejet Dispenser At Upcoming National Eyecare Meetings
Company to demonstrate mydcombi™ and avenova® and share data for clobetasol propionate ophthalmic suspension 0.05% at the american society of cataract and refractive surgery (ascrs) annual meeting, april 5-8, in boston
2024-03-18 16:05:00 - Press Release
Eyenovia Reports Fourth Quarter And Full-year 2023 Financial Results And provides Business Update
Announced fda approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery
2024-03-13 07:00:00 - Press Release
Novabay Pharmaceuticals And Eyenovia To Co-promote prescription Ophthalmic Products To U.s. Eyecare Professionals
Emeryville, calif. and new york, march 13, 2024 (globe newswire) -- novabay pharmaceuticals, inc. (nyse american: nby) and eyenovia, inc. (nasdaq: eyen) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the u.s. under the agreement, novabay will market eyenovia's clobetasol propionate ophthalmic suspension 0.05% (“clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its u.s. physician-dispensed channel. eyenovia will market novabay's prescription avenova® antimicrobial lid & lash solution through its mydcombi and clobetasol sales representatives strategically located across the u...
2024-03-11 07:00:00 - Press Release
Eyenovia To Report Fourth Quarter 2023 Results And Provide Business Update On monday, March 18th
Company to host an investor conference call and webcast at 4:30pm edt company to host an investor conference call and webcast at 4:30pm edt
Latest News
2024-04-09 10:31:19 - Zacks Investment Research
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
2024-03-18 20:52:10 - Seeking Alpha
Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript
2024-03-18 18:21:04 - Zacks Investment Research
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
2024-03-11 07:00:00 - GlobeNewsWire
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
2024-03-04 18:08:49 - Reuters
US FDA approves Eyenovia's eye drug, Formosa Pharma says
The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.
2024-02-26 14:45:19 - Seeking Alpha
Eyenovia: Racing Toward The Finish Line
Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company's manufacturing facilities, including two in the USA and one in Mexico, have received FDA certification, ensuring the safety and quality of their products. Eyenovia is preparing for the official launch of its first FDA-approved product, MydCombi, and has upcoming events, including financial results and an FDA decision for another drug.
2023-12-15 08:17:05 - InvestorPlace
7 Promising Penny Stocks With the Potential to Defy Expectations
2023-11-13 21:34:10 - Seeking Alpha
Eyenovia, Inc. (EYEN) Q3 2023 Earnings Call Transcript
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer Conference Call Participants John Boyle - William Blair Raymond Wu - Ladenburg Thalmann Len Yaffe - Stoc*Doc Partners Operator Good day, ladies and gentlemen. And welcome to Eyenovia's Third Quarter of 2023 Earnings Conference Call.
2023-11-09 08:16:09 - Zacks Investment Research
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
2023-11-06 08:00:00 - GlobeNewsWire
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT